Popular on TelAve
- OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors - 201
- Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth - 178
- ChargeOn Announces Conversational Payment Management Solution
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
- SafecomLink for Pactor – Hamradio Edition Launches in the WiMo Store
- Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
- Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
- New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views
- Badanamu and Friends Live Brings Hit Animated Series to Stages Across the United States
Similar on TelAve
- Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
- Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
- World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
- Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
- Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
- Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
- PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
2025 R&D Spending And Intensity Benchmarks
TelAve News/10905878
VIRGINIA BEACH, Va. - TelAve -- Schonfeld & Associates, Inc. has released the latest edition of its annual study R&D Ratios & Budgets. The new research report covers R&D spending and intensity in fiscal 2025 by more than 2,700 individual publicly traded companies within 280 industries. R&D Intensity, a key performance indicator, expresses a company's investment in research and development relative to its revenue. It is defined as the ratio of R&D spending to revenue.
The pharmaceutical industry continues to be the biggest R&D investor in fiscal 2025 with budgets of drug companies increasing slightly to $195 billion. Software companies contributed a total of over $132 billion to this investment pool.
The biggest single R&D investor in 2025 was Amazon at over $108 billion, followed by Alphabet at $61 billion, and then Meta, Microsoft and Apple at over $31 billion each. Firms involved with digital content are investing much more heavily than those in more traditional arenas.
Pharmaceutical firms continued significant R&D spending in 2025. Merck, the top spender at $15.7 billion, is followed by Johnson & Johnson, Astrazeneca, AbbVie, Eli Lilly, Pfizer, and Novartis each spending over $10 billion. The biotech industry, led by Amgen, decreased R&D spending by nearly 8% to $36 billion. Electromedical apparatus makers, led by Medtronic, spent a total of over $3.5 billion, an increase of 2% over 2024.
More on TelAve News
R&D budgets of semiconductor makers grew to over $93 billion, an increase of over 13%. Nvidia had the largest R&D budget, $18 billion, a 43% increase from 2024. Major suppliers to the infrastructure of the Internet cloud continue robust R&D spending to remain competitive.
The 2025 R&D spending of the automotive industry, led by Stellantis, Toyota, Honda, Ford and General Motors each spending over $8 billion, was up over 24% from the 2024 total with industry revenues up over 2%.
R&D Ratios & Budgets is an essential reference presenting R&D spending and intensity information published annually by Schonfeld & Associates, Inc. The study is based on 10-K annual report information submitted to the U.S. Securities & Exchange Commission.
R&D Ratios & Budgets contains information for each of the over 2,700 individual publicly traded companies. Fiscal year 2025 revenue and R&D spending are listed as well as annual growth rates of each. R&D intensity for 2025 is presented along with the lowest and highest R&D Intensity ratio during the past five years. The range of values gives an insight into the stability of the firm's commitment to funding R&D as well as its direction.
More on TelAve News
The industry summary section within R&D Ratios & Budgets presents for each of 280 industries: total fiscal year 2025 revenue and R&D spending as well as annual growth rates of each. The industry R&D intensity ratio for 2025 is listed so that an individual company's value can be compared to the value for the industry as a whole and to answer the question: Is this company leading or lagging its peers in prioritizing innovation?
To allow for further investigation, two Excel datafiles are available for purchase along with the PDF report. Each contains five years of revenue, R&D spending and R&D intensity information. One file contains company data and the other industry information.
The 2026 edition of the R&D Ratios & Budgets PDF study is $395 and the study along with Excel datafiles is $495. Contact Schonfeld & Associates, Inc., 1932 Terramar Lane, Virginia Beach, VA 23456. Call for more information or to place an order: 800-205-0030 or visit https://www.saibooks.com/product/r-d-ratios-budgets-2 for immediate download.
The pharmaceutical industry continues to be the biggest R&D investor in fiscal 2025 with budgets of drug companies increasing slightly to $195 billion. Software companies contributed a total of over $132 billion to this investment pool.
The biggest single R&D investor in 2025 was Amazon at over $108 billion, followed by Alphabet at $61 billion, and then Meta, Microsoft and Apple at over $31 billion each. Firms involved with digital content are investing much more heavily than those in more traditional arenas.
Pharmaceutical firms continued significant R&D spending in 2025. Merck, the top spender at $15.7 billion, is followed by Johnson & Johnson, Astrazeneca, AbbVie, Eli Lilly, Pfizer, and Novartis each spending over $10 billion. The biotech industry, led by Amgen, decreased R&D spending by nearly 8% to $36 billion. Electromedical apparatus makers, led by Medtronic, spent a total of over $3.5 billion, an increase of 2% over 2024.
More on TelAve News
- Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
- Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
- Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
- Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
R&D budgets of semiconductor makers grew to over $93 billion, an increase of over 13%. Nvidia had the largest R&D budget, $18 billion, a 43% increase from 2024. Major suppliers to the infrastructure of the Internet cloud continue robust R&D spending to remain competitive.
The 2025 R&D spending of the automotive industry, led by Stellantis, Toyota, Honda, Ford and General Motors each spending over $8 billion, was up over 24% from the 2024 total with industry revenues up over 2%.
R&D Ratios & Budgets is an essential reference presenting R&D spending and intensity information published annually by Schonfeld & Associates, Inc. The study is based on 10-K annual report information submitted to the U.S. Securities & Exchange Commission.
R&D Ratios & Budgets contains information for each of the over 2,700 individual publicly traded companies. Fiscal year 2025 revenue and R&D spending are listed as well as annual growth rates of each. R&D intensity for 2025 is presented along with the lowest and highest R&D Intensity ratio during the past five years. The range of values gives an insight into the stability of the firm's commitment to funding R&D as well as its direction.
More on TelAve News
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
- Modern Network Infrastructure with 6WIND vCGNAT
- Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
The industry summary section within R&D Ratios & Budgets presents for each of 280 industries: total fiscal year 2025 revenue and R&D spending as well as annual growth rates of each. The industry R&D intensity ratio for 2025 is listed so that an individual company's value can be compared to the value for the industry as a whole and to answer the question: Is this company leading or lagging its peers in prioritizing innovation?
To allow for further investigation, two Excel datafiles are available for purchase along with the PDF report. Each contains five years of revenue, R&D spending and R&D intensity information. One file contains company data and the other industry information.
The 2026 edition of the R&D Ratios & Budgets PDF study is $395 and the study along with Excel datafiles is $495. Contact Schonfeld & Associates, Inc., 1932 Terramar Lane, Virginia Beach, VA 23456. Call for more information or to place an order: 800-205-0030 or visit https://www.saibooks.com/product/r-d-ratios-budgets-2 for immediate download.
Source: Schonfeld & Associates, Inc.
0 Comments
Latest on TelAve News
- Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- iPhone 18 Pro Genuine Cowhide Case | Vintage iPhone Case | Distressed iPhone Case
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
- JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
- Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- Building Smarter Networks with Cloud-Native Technology
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
- Revenue Optics Names Prat Patibandla Director of Growth Marketing
